ABM Therapeutics has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for ABM-1310 to treat patients with glioblastoma (GBM) harbouring the BRAF V600 mutation.
A small-molecule BRAF inhibitor, ABM-1310 is an orally administered medicine with high BRAF mutation selectivity, blood-brain barrier permeability and water solubility.
Go deeper with GlobalData
The inhibitor is currently in Phase I trials at clinical sites in China and the US, targeting advanced solid tumours with the BRAF V600 mutation.
Interim results from the US Phase I trial showed that ABM-1310 exhibited promising anti-cancer activity and a good safety profile in patients with advanced solid tumours, including primary brain tumours such as GBM and other gliomas.
In China, a new Phase I clinical study focused specifically on GBM has recently commenced.
GBM is a hard-to-treat and extremely aggressive brain tumour. Its treatment remains a significant challenge owing to tumorigenesis complexities and resistance to the therapy.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataTraditional treatments such as surgical resection, radiation therapy and chemotherapy have limitations.
ABM Therapeutics, a clinical-stage biopharmaceutical company, focuses on small molecule research and the development of new medicines to treat cancer, specifically brain cancer and brain metastases from solid tumours.
ABM has been developing a pipeline for the construction of a brain medicine research and development platform known as BPKdd. The pipeline comprises several programmes at different stages of discovery and development.
